Highest-materiality recent filing
David Lowrance resigns as CFO & CAO eff. July 15, 2026 due to health; receives severance and 12-month equity vesting acceleration.
Savara amends Hercules loan; adds $75M drawdown tied to FDA approval of MOLBREEVI
Amends $105M loan agreement; new $45M and $30M tranches available upon FDA approval of MOLBREEVI for aPAP.
Savara prices $130M public offering of common stock and pre-funded warrants at $4.20/share
23.8M shares at $4.20/share and 7.1M pre-funded warrants at $4.199/warrant for gross proceeds of $130M.
Savara secures $75M royalty funding from RTW for MOLBREEVI; also discloses securities class action
RTW commits $75M upon FDA approval of MOLBREEVI for autoimmune PAP; funds to support U.S. launch and repay debt.
Savara receives FDA Refusal to File for MOLBREEVI BLA; resubmission expected Q4 2025
FDA requested additional CMC data; RTF not due to safety or efficacy concerns.
Savara secures up to $200M non-dilutive debt from Hercules Capital, $30M drawn at close
$30M initial draw used to repay existing $26.5M SVB debt; up to $170M additional available contingent on FDA approval of MOLBREEVI and other milestones.
Savara prices $100M common stock offering at $3.81/sh, 26.2M shares
Gross proceeds of ~$100M from 26,246,720 shares at $3.81 per share.
Savara reports positive Phase 3 IMPALA-2 results for molgramostim in aPAP; primary endpoint met
Primary endpoint met: DLCO improved by 6.00% predicted at Week 24 vs placebo (p=0.0007).
Savara prices $80M underwritten offering of common stock and pre-funded warrants at $3.00/share
Offering of 21M common shares at $3.00/share and 5.67M pre-funded warrants at $2.999/warrant for $80M gross proceeds.
Savara appoints Robert Lutz as COO with $437K salary, $115K signing bonus
Robert Lutz, former CFO/COO of iBio and Strongbridge, joins Savara as COO effective Feb 13, 2023.
Savara enters $60M at-the-market equity offering program with Evercore
Savara signs Sales Agreement with Evercore to sell up to $60M of common stock in ATM offerings.
Mr. Lutz's appointment follows the decision of David Lowrance to resign from his role as Savara's Chief Financial and Administrative Officer, effective as of the Effective Date, due to health reasons.
On June 5, 2026, the Board appointed Robert Lutz to become the Chief Financial and Operating Officer of Savara effective July 15, 2026 (the "Effective Date").
On April 10, 2024, Dr. Ricky Sun notified the Board of Directors (the “Board”) of Savara Inc. (the “Company”) of his intention not to stand for reelection to the Board following the expiration of his current term at the 2024 Annual Meeting of Stockholders (the “Annual Meeting”).
On February 13, 2023 (the “Effective Date”), Robert Lutz joined Savara Inc. (“Savara”) as its Chief Operating Officer.
On the Effective Date, the Board of Directors (the “Board”) of Savara appointed Dave Lowrance, who has served as Savara’s Chief Financial Officer since November 2016, as Chief Financial and Administrative Officer of Savara.
On August 24, 2022, Dr. Badrul Chowdhury notified Savara Inc. (“Savara”) of his decision to resign as Chief Medical Officer of Savara.
Max materiality 0.90 · Median 0.40 · Most common event other_material